(NYSE:JPM) stock a Strong Buy, 0 rate the stock a Buy, 9 rate Hold, 0 rate Sell and 1 recommend a Strong Sell. The financial services provider reported $1.65 EPS for the quarter, topping the Zacks' consensus estimate of $1.52 by $0.13.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced the company now believes that the cash, cash equivalents and marketable securities at March 31, 2017 combined with the anticipated proceeds from future sales of common stock under Cantor agreement, are sufficient to meet estimated working capital requirements and fund planned operations through 2018. Thomas J. Herzfeld Advisors Inc. acquired a new position in JPMorgan Chase & Co. during the fourth quarter valued at approximately $125,000.
Other hedge funds and other institutional investors have also bought and sold shares of the company. On Friday, January 13 Petno Douglas B sold $566,195 worth of JPMorgan Chase & Co. Comprehensive Portfolio Management LLC purchased a new stake in shares of JPMorgan Chase & Co. during the fourth quarter valued at approximately $631,000.
Total debt to equity ratio of the company for most recent quarter is 1.54 while Long term debt to equity ratio for same time period is 1.52. Finally, Hunter Associates Investment Management LLC raised its position in shares of JPMorgan Chase & Co.by 0.7% in the fourth quarter. Analysts are forecasting earnings of $1.63 on a per share basis this quarter. Analysts reported that the Price Target for JPMorgan Chase & Co. might touch $108 high while the Average Price Target and Low price Target is $93.11 and $77 respectively. Since the open, shares have moved 0.38% after recently hitting the $87.33 mark. 8,334,867 shares of the stock traded hands. The stock has a 50 day moving average of $86.91 and a 200 day moving average of $84.46. The company's market cap is $310.26 Billion, and the average volume is 15.56 Million.
JPMorgan Chase & Co. had a return on equity of 10.91% and a net margin of 23.45%. (NYSE:JPM) last issued its earnings results on Thursday, April 13th. The difference between the expected and actual EPS was $0.13/share, which represents an Earnings surprise of 8.6%. The company had revenue of $25.59 billion for the quarter, compared to the consensus estimate of $24.40 billion. Equities research analysts predict that JPMorgan Chase & Co. will post $6.70 EPS for the current year. Investors of record on Thursday, April 6th were given a dividend of $0.50 per share. The ex-dividend date of this dividend was Tuesday, April 4th.
Historically, if we have a peek at price target revisions, JPMorgan Chase & Co.
Gal Gadot: I was raised to be a confident woman with aspirations
Given that she was easily the most appealing thing about Batman v Superman, that's probably a good idea. That depends on what kind of buzz about the movie emerges from that crucial first weekend.
The target price for JPMorgan Chase & Co.
Southern Missouri Bancorp, Inc.is the holding firm for Southern Bank.
Shares of JPMorgan Chase & Co. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & worldwide trademark and copyright law. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/05/11/pagnatokarp-partners-llc-acquires-new-position-in-jpmorgan-chase-co-jpm-updated.html. Analyst's mean target price for JPM is $94.02 while analysts mean recommendation is 2.30. Stock has got OUTPERFORM rating from 9 analysts of Thomson Reuters, 11 analysts given HOLD rating to the stock and 1 given UNDERPERFORM rating. Daiwa Capital Markets upgraded shares of JPMorgan Chase & Co. from a "hold" rating to an "outperform" rating in a research report on Tuesday, February 7th. Finally, Oppenheimer Holdings Inc. reaffirmed a hold rating on shares of JPMorgan Chase & Co.in a report on Wednesday, January 11th. Argus Research maintained the stock with "Buy" rating in Friday, January 15 report.
When it comes to the Analysis of a Stock, Price Target plays a vital role.
In related news, COO Matthew E. Zames sold 3,405 shares of the business's stock in a transaction dated Monday, April 17th.
Bremer Trust National Association increased Hca Holdings Inc (NYSE:HCA) stake by 5,001 shares to 25,934 valued at $1.92M in 2016Q4. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Stacey Friedman sold 10,792 shares of the company's stock in a transaction that occurred on Monday, April 17th. The shares were purchased at an average price of $85.48 per share, for a total transaction of $983,020.00. Following the sale, the chief operating officer now owns 329,019 shares in the company, valued at approximately $27,986,356.14. The disclosure for this sale can be found here.
Comments